Clinical Trial Update: Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Topotecan + Cisplatin vs Etoposide + Cisplatin as first-line therapy for extensive-disease small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Etoposide (Etoposide)
• Topotecan (topotecan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Small Cell | Phase 3 | Status: COMPLETED